Get the Stockscreener App
10.89
0.00%
0.00
After Hours:
10.67
-0.22
-2.02%
Satellos Bioscience Inc stock is traded at $10.89, with a volume of 59,626.
It is up +0.00% in the last 24 hours and up +0.00% over the past month.
Satellos Bioscience Inc is a regenerative medicine company a biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.
See More
Previous Close:
$10.89
Open:
$11.16
24h Volume:
59,626
Relative Volume:
66.00
Market Cap:
$168.35M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.00%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$10.89
$11.81
1-Week Range:
$10.89
$11.81
52-Week Range:
$10.89
$11.81
Satellos Bioscience Inc Stock (MSLE) Company Profile
Name
Satellos Bioscience Inc
Sector
Industry
Phone
-
Address
-
Compare MSLE vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MSLE
Satellos Bioscience Inc
|
10.89 | 173.91M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.87 | 121.26B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.28 | 83.04B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
828.24 | 50.22B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.00 | 43.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
348.85 | 39.16B | 4.98B | 69.60M | 525.67M | 0.5198 |
Satellos Bioscience Inc Stock (MSLE) Latest News
Satellos Bioscience Completes $57.2 Million Public Offering - marketscreener.com
Satellos Closes US$57.2 Million Public Offering in Canada and the United States - marketscreener.com
Satellos Bioscience raises $57.2 million in public offering By Investing.com - Investing.com India
Satellos Brief: Closes US$57.2M Public Offer in Canada and United States, Including Exercise of Underwriters' Option to Purchase Additional Shares - marketscreener.com
Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise of Underwriters’ Option to Purchase Additional Shares - Business Wire
(MSCL) Equity Market Report (MSCL:CA) - Stock Traders Daily
Satellos prices $50M public offering - MSN
Satellos Raises US$50 Million in Cross-Border Offering as Shares Debut on Nasdaq - TipRanks
Satellos Bioscience prices $50 million public offering - Investing.com
Canadian Investment Regulatory Organization Trading HaltMSCL - marketscreener.com
Satellos announces pricing of US$50 million public offering in Canada and the United States - marketscreener.com
Satellos Announces Pricing of US$50 Million Public Offering in Canada and the United States - Business Wire
Satellos Announces Launch of Public Offering in Canada and the United States and Filing of Applicati - PharmiWeb.com
Satellos announces launch of public offering in Canada and the United States and filing of application to list on Nasdaq - marketscreener.com
Satellos launches public offering, applies for Nasdaq listing - MSN
Satellos Plans Cross-Border Share Offering and Nasdaq Listing to Fund Muscle Disease Pipeline - TipRanks
Satellos Announces Launch of Public Offering in Canada and the United States and Filing of Application to List on Nasdaq - marketscreener.com
(MSCL) Advanced Trading Insights (MSCL:CA) - Stock Traders Daily
(MSCL) Strategic Equity Report (MSCL:CA) - Stock Traders Daily
Satellos appoints Antoinette Paone as chief development officer and head of Regulatory Affairs - marketscreener.com
Satellos appoints Antoinette Paone as chief development officer By Investing.com - Investing.com Australia
Satellos Bioscience Inc. - Menafn.com
Satellos Bioscience Taps Antoinette Paone as Chief Development Officer - Contract Pharma
Satellos Strengthens Executive Bench With Veteran Regulator as Duchenne Program Advances - TipRanks
Satellos Biosciences Brief: Appointing Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs - marketscreener.com
Satellos Bioscience Welcomes New Chief Development Officer - GuruFocus
(MSCL) Technical Pivots with Risk Controls (MSCL:CA) - Stock Traders Daily
Satellos Bioscience Brief: Announcing Share Consolidation in Connection with Proposed Nasdaq Listing - marketscreener.com
Satellos announces share consolidation in connection with proposed Nasdaq listing - marketscreener.com
(MSCL) Advanced Equity Analysis (MSCL:CA) - Stock Traders Daily
(MSCL) Technical Data (MSCL:CA) - Stock Traders Daily
(MSCL) Stock Analysis and Trading Signals (MSCL:CA) - Stock Traders Daily
Satellos Receives Clearance by U.S. FDA and Global Regulators to Initiate Pediatric Phase 2 Study of SAT-3247 for Duchenne Muscular Dystrophy - BioSpace
Satellos receives FDA clearance for phase 2 Duchenne trial - Investing.com
Satellos Tackles Duchenne ‘As Stem Cell People Solving a Stem Cell Problem’ - Citeline News & Insights
Satellos to Participate in December Investor Conferences - Business Wire
Does DMD start in the womb? New research challenges old beliefs. - Muscular Dystrophy News
Satellos Announces Publication in Nature Communications Supporting its Novel Treatment Approach for Duchenne Muscular Dystrophy - BioSpace
Satellos Reports Third Quarter 2025 Results and Announces Appointment of Mark Nawacki to Board of Directors - BioSpace
Oral therapy moves to follow-up after strong data in DMD adults - Muscular Dystrophy News
Satellos Announces First Adult Patient Dosed in LT-001, an Open-Label, Long-Term Follow-Up Study of SAT-3247 in Duchenne Muscular Dystrophy - BioSpace
Satellos Announces New Data Further Demonstrating Safety, Tolerability, and Functional Impact of SAT-3247 in First-in-Human Trial of Adults with Duchenne Muscular Dystrophy - BioSpace
Satellos asks FDA to clear Phase 2 trial of DMD treatment - Muscular Dystrophy News
Satellos to Present SAT-3247 Phase 1 Clinical Data in Late-Breaking Poster Session at the 2025 World Muscle Society Congress - Investing News Network
Doubled Grip Strength: Satellos' Novel DMD Drug Heads to Phase 2 Trial After Promising Adult Results - stocktitan.net
Satellos to Participate in Four September Institutional and Retail Investor Conferences - Investing News Network
Here's Why We're Watching Satellos Bioscience's (TSE:MSCL) Cash Burn Situation - Yahoo Finance
Satellos Bioscience: Promising Novel Treatment For Duchenne Muscular Dystrophy (TSX:MSCL:CA) - Seeking Alpha
Satellos Reports Second Quarter 2025 Results and Highlights Upcoming Clinical Milestones - Investing News Network
Encouraging Results from Phase 1 Trials, Says Satellos Chief Scientific Officer. Now It's On to Phase 2 - Managed Healthcare Executive
DMD treatment SAT-3247 safe in trial, shows early signs of efficacy - Muscular Dystrophy News
Satellos Bioscience Inc Stock (MSLE) Financials Data
There is no financial data for Satellos Bioscience Inc (MSLE). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.10%
7.16%
Cap:
|
Volume (24h):